HARROW HEALTH, INC.

Profile

Company Names

HARROW HEALTH, INC.
IMPRIMIS PHARMACEUTICALS, INC.

Addresses

102 WOODMONT BLVD., SUITE 610, NASHVILLE, TN 37205

12264 EL CAMINO REAL, SUITE 350, SAN DIEGO, CA 92130

437 S. HWY 101, STE 209, SOLANA BEACH, CA 92075

Phone Numbers

(615) 733-4730
858-704-4040
858-433-2800

 

Entity Type:

CORPORATION

Industry:

PHARMACEUTICALS

Year Incorporated:

> 5 years ago

State Incorporated:

DELAWARE

Total Amount Raised:

$29,184,920.00

Number of Funding Rounds:

4
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
4
2021-05-05 
$10,670,000.00 
$10,670,000.00 
$0.00 
Equity 
3
2016-12-27 
$10,068,740.00 
$10,068,740.00 
$0.00 
Equity 
2
2015-01-01 
$500,000.00 
$818,750.00 
$318,750.00 
Equity 
1
2012-04-25 
$7,946,180.00 
$7,946,180.00 
$0.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
JEFFREY 
 
ABRAMS 
DIRECTOR
ORPHEUS HOLDINGS LLC   |  NZC OPPORTUNITIES II LLC   |  ORPHEUS HOLDINGS LTD   |  IMPRIMIS PHARMACEUTICALS, INC.   |  GUGGENHEIM PRIVATE DEBT FUND LTD   |  GUGGENHEIM PRIVATE DEBT FUND, LLC   |  GUGGENHEIM LOAN FUND, LLC   |  GUGGENHEIM HIGH-YIELD FUND, LLC   |  GUGGENHEIM PRIVATE DEBT FUND NOTE ISSUER 2.0, LLC   |  GUGGENHEIM PRIVATE DEBT FUND 2.0, LTD.   |  GUGGENHEIM PRIVATE DEBT FUND 2.0, LLC   |  GUGGENHEIM PRIVATE DEBT FUND 2.0-I, LLC
STEPHEN 
 
AUSTIN 
DIRECTOR
QUETZAL ENERGY INC.   |  QUETZAL ENERGY LTD.   |  IMPRIMIS PHARMACEUTICALS, INC.   |  PRESERVATION FUND IV LLP
STEPHEN 
G. 
AUSTIN 
DIRECTOR
IMPRIMIS PHARMACEUTICALS, INC.
MARK 
 
BAUM 
EXECUTIVE OFFICER, DIRECTOR
IMPRIMIS PHARMACEUTICALS, INC.   |  ETON PHARMACEUTICALS, INC.   |  SURFACE PHARMACEUTICALS, INC.   |  MELT PHARMACEUTICALS, INC.   |  SURFACE OPHTHALMICS, INC.
MARK 
L 
BAUM 
EXECUTIVE OFFICER
ETON PHARMACEUTICALS, INC.   |  HARROW HEALTH, INC.
MARK 
L. 
BAUM 
EXECUTIVE OFFICER, DIRECTOR
SHRINK NANOTECHNOLOGIES, INC.   |  IDEAL POWER INC.   |  ENDRA, INC.   |  IMPRIMIS PHARMACEUTICALS, INC.
ANDREW 
 
BOLL 
EXECUTIVE OFFICER
IMPRIMIS PHARMACEUTICALS, INC.   |  ETON PHARMACEUTICALS, INC.   |  MELT PHARMACEUTICALS, INC.
ANDREW 
R 
BOLL 
EXECUTIVE OFFICER
HARROW HEALTH, INC.
ANDREW 
R. 
BOLL 
EXECUTIVE OFFICER
IMPRIMIS PHARMACEUTICALS, INC.
BALBIR 
 
BRAR 
EXECUTIVE OFFICER, DIRECTOR
IMPRIMIS PHARMACEUTICALS, INC.
PAUL 
 
FINNEGAN 
DIRECTOR
IMPRIMIS PHARMACEUTICALS, INC.   |  MUSTANG INVESTMENT HOLDINGS L.P.   |  MDP HC HOLDINGS, LLC   |  CDW CORP   |  MDP ACM HOLDINGS, LLC   |  MDP SM HOLDINGS, LLC   |  ANGIOCRINE BIOSCIENCE, INC.   |  PROCURATED, INC.   |  PINE STREET HEALTHCARE HOLDINGS, LLC   |  PSHUH, LLC   |  RIVER SEA PSCP ROOFING INVESTOR LLC   |  ALIGNED EXTERIORS GROUP LLC
ROBERT 
 
KAMMER 
DIRECTOR
IMPRIMIS PHARMACEUTICALS, INC.   |  SOFT SCIENCE, INC.
ROBERT 
J 
KAMMER 
DIRECTOR
HARROW HEALTH, INC.
ROBERT 
J. 
KAMMER 
DIRECTOR
IMPRIMIS PHARMACEUTICALS, INC.
RICHARD 
 
LINDSTROM 
DIRECTOR
VERTICAL HEALTH SOLUTIONS INC   |  OCULAR THERAPEUTIX, INC   |  FORSIGHT VISION6, INC.   |  ENCORE VISION, INC.   |  ALPHAEON CORP   |  TEARLAB CORP   |  POGOTEC, INC.   |  IMPRIMIS PHARMACEUTICALS, INC.   |  SIGHTLIFE SURGICAL, INC.   |  UNITED VISION PARTNERS HOLDINGS, LLC   |  EQUINOX, INC.   |  IANTECH, INC.   |  CORNEAGEN INC.   |  EQUINOX OPHTHALMIC, INC.   |  THEROPTIX, INC.   |  LENTECHS LLC   |  SURFACE OPHTHALMICS, INC.   |  SYDNEXIS, INC.   |  CG HOLDING CO.   |  IOR HOLDINGS, INC.   |  VINCI PHARMACEUTICALS, INC.
RICHARD 
L 
LINDSTROM 
DIRECTOR
OCCULOGIX, INC.   |  SILK TECHNOLOGIES, LTD.   |  HARROW HEALTH, INC.
RICHARD 
L. 
LINDSTROM 
DIRECTOR
TEARLAB CORP   |  ELENZA, INC   |  IMPRIMIS PHARMACEUTICALS, INC.   |  SURFACE PHARMACEUTICALS, INC.   |  OCULAR THERAPEUTIX, INC   |  LENSAR, INC.   |  EYEMACULAR REGENERATION, INC.
WILLIAM 
H. 
NELSON 
DIRECTOR
IMPRIMIS PHARMACEUTICALS, INC.
ANTHONY 
 
PRINCIPI 
DIRECTOR
IMPRIMIS PHARMACEUTICALS, INC.
JOACHIM 
 
SCHUPP 
EXECUTIVE OFFICER
IMPRIMIS PHARMACEUTICALS, INC.   |  EMERALD HEALTH PHARMACEUTICALS INC.
TERESA 
F 
SPARKS 
DIRECTOR
HARROW HEALTH, INC.
R 
LARRY 
VAN HORN 
DIRECTOR
HARROW HEALTH, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2021-05-14
D
Link
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
$25,000,001 - $100,000,000 
Equity 
2021-05-05 
2016-12-30
D
Link
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2016-12-27 
2015-01-15
D
Link
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2015-01-01 
2012-05-03
D
Link
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2012-04-25 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
N/A
NONE
NATIONAL SECURITIES CORPORATION
7569